Once diagnosed with symptomatic myeloma, younger and/or relatively more physically fit patients, as determined by a haematologist, receive a combination of drugs such as anti-CD38 monoclonal antibody (mAb) therapy (e.g., daratumumab) alongside bortezomib, thalidomide, and dexamethasone (D-VTD) to control and manage the disease prior to a haematopoietic stem cell transplant (Moreau et al., 2019). The gene discussed is CD38; the disease is plasma cell myeloma.